Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Key Inclusion Criteria:

1. Patients with advanced HCC

2. For the Phase 2 portion of the study, at least 1 measurable tumor lesion according to
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, which has not been
previously treated with local therapy

3. Cirrhotic status of Child-Pugh Class A only

4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

5. The following laboratory parameters:

- Albumin ≥ 2.8 g/dL

- Platelet count ≥ 60,000/mm3

- Absolute neutrophil count (ANC) ≥ 1500/mm3

- Hemoglobin ≥ 8.5 g/dL

- Total bilirubin ≤ 3 mg/dL

- Alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) ≤ 3 times
upper limit of normal (ULN)

- Amylase and lipase ≤ 1.5 times ULN

- Calculated or measured creatinine clearance (CrCl) ≥ 30 mL/min

- Prothrombin time (PT)-international normalized ratio (INR) ≤ 2.3 or PT ≤ 6
seconds above control

Key Exclusion Criteria:

1. Previous or concurrent cancer that is distinct in primary site or histology from HCC,
EXCEPT cervical and breast carcinoma in situ, adequately treated basal cell or
squamous cell carcinoma of the skin, or superficial bladder tumors (Ta, Tis & T1)

2. Renal failure requiring hemo- or peritoneal dialysis

3. History of cardiac disease

4. Active clinically serious infections. Hepatitis B is allowed if no active replication
is present. Hepatitis C is allowed if no antiviral treatment is required

5. Known history of human immunodeficiency virus (HIV) infection

6. Known history or symptomatic metastatic brain or meningeal tumors

7. Clinically significant gastrointestinal (GI) bleeding, serious nonhealing wound and
ulcer within 3 months prior to study entry, or bone fracture within 30 days prior to
study entry

8. History of organ allograft

9. Known or suspected allergy to the investigational agent or any agent given in
association with this trial

10. Inability to swallow medication, inability or unwillingness to comply with the drug
administration requirements, or GI condition that could interfere with the oral
absorption or tolerance of treatment

11. Uncontrolled diabetes

12. Any contraindication to oral hydration (e.g., preexisting cardiac impairment or fluid
restriction)

13. Uncontrolled ascites

14. Pleural effusion or ascites that causes respiratory compromise (NCI-CTCAE ≥ Grade 2
dyspnea).

15. Women who are pregnant and/or breastfeeding

16. Prior use of any systemic anticancer chemotherapy for HCC

17. Prior use of systemic investigational agents for HCC

18. Concomitant treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors

19. Known hypersensitivity or intolerance to dexamethasone or 5-HT3 antagonist